



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SCHWEIGHOFFER et al.

Atty. Ref.: 3665-152; Confirmation No.

Appl. No. 10/541,503

TC/A.U. To be assigned

Filed: July 7, 2005

Examiner: To be assigned

For: METHODS AND COMPOSITIONS FOR THE TREATMENT OF DEGENERATIVE
OCULAR PATHOLOGIES

* * * * *

April 2, 2009

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE

Responsive to the Official Action dated March 3, 2009, the applicants elect the subject matter of the Examiner's Group I for further prosecution in the above.

The applicants elect, for the purpose of initial examination and without prejudice, Etazolate, as a PDE4 inhibitor, and Age-Related Macular Degeneration (ARMD), as an ocular disease. Claims 21-26, 29-31, 33 and 36, of the elected Group read on the elected species.

An early and favorable Action on the merits of the claimed invention is requested.

SCHWEIGHOFFER et al.
Appl. No. 10/541,503
Atty. Ref.: 3665-152
Response
April 2, 2009

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
 B. J. Sadoff
 Reg. No. 36,663

BJS:
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100